Synapse - Helena Yu

Search Within

Helena Alexandra Yu

Results (292)

Chemo-immunotherapy outcomes of KRAS-G12C mutant lung cancer compared to other molecular subtypes of KRAS-mutant lung cancer

Meeting Abstract

Arbour, K. C.; Ricciuti, B.; Rizvi, H.; Hellmann, M. D.; Yu, H. A.; Ladanyi, M.; Kris, M. G.; Arcila, M. E.; Rudin, C. M.; Lito, P.; more...
Journal of Clinical Oncology (2021)

Fulltext@MSK | Save

Biomarker-directed phase II platform study in patients with EGFR sensitizing mutation-positive advanced/metastatic non-small cell lung cancer whose disease has progressed on first-line osimertinib therapy (ORCHARD)

Journal Article

Yu, H. A.; Goldberg, S. B.; Le, X.; Piotrowska, Z.; Goldman, J. W.; De Langen, A. J.; Okamoto, I.; Cho, B. C.; Smith, P.; Mensi, I.; more...
Clinical Lung Cancer (2021)

Fulltext@MSK | Save

Multi-omic characterization of lung tumors identify AKT and EZH2 as potential therapeutic targets in adenocarcinoma-to-squamous transdifferentiation

Meeting Abstract

Quintanal-Villalonga, Á.; Taniguchi, H.; Zhan, Y. A.; Hasan, M. M.; Chavan, S. S.; Uddin, F.; Allaj, V.; Manoj, P.; Shah, N.; Ciampricotti, M.; more...
Annals of Oncology (2021)

Fulltext@MSK | Save

Multi-omic characterization of lung tumors implicates AKT and MYC signaling in adenocarcinoma to squamous cell transdifferentiation

Meeting Abstract

Quintanal-Villalonga, A.; Taniguchi, H.; Zhan, Y. A.; Hasan, M. M.; Chavan, S. S.; Uddin, F.; Allaj, V.; Manoj, P.; Shah, N. S.; Chan, J. M.; more...
Annals of Oncology (2021)

Fulltext@MSK | Save

ORCHARD osimertinib + savolitinib interim analysis: A biomarker-directed phase II platform study in patients (pts) with advanced non-small cell lung cancer (NSCLC) whose disease has progressed on first-line (1L) osimertinib

Meeting Abstract

Yu, H. A.; Ambrose, H.; Baik, C.; Cho, B. C.; Cocco, E.; Goldberg, S. B.; Goldman, J. W.; Kraljevic, S.; de Langen, A. J.; Okamoto, I.; more...
Annals of Oncology (2021)

Fulltext@MSK | Save

Comprehensive molecular characterization of lung tumors implicates AKT and MYC signaling in adenocarcinoma to squamous cell transdifferentiation

Journal Article

Quintanal-Villalonga, A.; Taniguchi, H.; Zhan, Y. A.; Hasan, M. M.; Chavan, S. S.; Meng, F.; Uddin, F.; Allaj, V.; Manoj, P.; Shah, N. S.; more...
Journal of Hematology & Oncology (2021)

Fulltext@MSK | Save

Targeting Aurora B kinase prevents and overcomes resistance to EGFR inhibitors in lung cancer by enhancing BIM- and PUMA-mediated apoptosis

Journal Article

Tanaka, K.; Yu, H. A.; Yang, S.; Han, S.; Selcuklu, S. D.; Kim, K.; Ramani, S.; Ganesan, Y. T.; Moyer, A.; Sinha, S.; more...
Cancer Cell (2021)

Fulltext@MSK | Save

Updated efficacy and safety of patritumab deruxtecan (HER3-DXd; U3-1402), a HER3 directed antibody drug conjugate, in EGFRm NSCLC

Meeting Abstract

Hayashi, H.; Yu, H. A.; Baik, C.; Gold, K.; Johnson, M. L.; Koczywas, M.; Murakami, H.; Nishio, M.; Steuer, C.; Su, W. C.; more...
Annals of Oncology (2021)

Fulltext@MSK | Save

Identification of optimal dosing schedules of dacomitinib and osimertinib for a phase I/II trial in advanced EGFR-mutant non-small cell lung cancer

Journal Article

Poels, K. E.; Schoenfeld, A. J.; Makhnin, A.; Tobi, Y.; Wang, Y.; Frisco-Cabanos, H.; Chakrabarti, S.; Shi, M.; Napoli, C.; McDonald, T. O.; more...
Nature Communications (2021)

Fulltext@MSK | Save

Enhanced specificity of clinical high-sensitivity tumor mutation profiling in cell-free DNA via paired normal sequencing using MSK-ACCESS

Journal Article

Brannon, A. R.; Jayakumaran, G.; Diosdado, M.; Patel, J.; Razumova, A.; Hu, Y.; Meng, F.; Haque, M.; Sadowska, J.; Murphy, B. J.; more...
Nature Communications (2021)

Fulltext@MSK | Save